{"id":"NCT01223937","sponsor":"Ferring Pharmaceuticals","briefTitle":"Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients","officialTitle":"A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-10-19","resultsPosted":"2015-10-15","lastUpdate":"2015-10-15"},"enrollment":268,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"Desmopressin","otherNames":["FE992026","MINIRIN®","Nocturin®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Desmopressin 25 μg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia.","primaryOutcome":{"measure":"Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period","timeFrame":"Day 1 (Baseline); Week 1, Months 1, 2, 3 (3-month treatment period)","effectByArm":[{"arm":"Placebo","deltaMin":-1,"sd":0.94},{"arm":"Desmopressin 25 μg","deltaMin":-1.21,"sd":0.957}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0280"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Canada"]},"refs":{"pmids":["23454404","27862898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":126},"commonTop":["Urinary tract infection","Headache"]}}